Aims: To assess adrenal function in asthmatic children treated with inhaled fluticasone propionate for up to 16 weeks.
Methods: Children with asthma and bronchial hyperresponsiveness to inhaled methacholine were treated with inhaled fluticasone 250–750 μg/day via Volumatic spacer. The insulin tolerance test (ITT) was performed to assess adrenal function.
Results: Eighteen asthmatic patients (10 boys, 8 girls), aged 7–17 years received inhaled fluticasone therapy at a median dose of 477 μg/m2 per day for 5–16 weeks. Adrenal suppression, defined as 60 minute serum cortisol less than 500 nmol/l, was found in 9 of 18 children. Following the ITT, the median basal and 60 minute serum cortisol concentrations of the suppressed group were 135.0 and 350.0 nmol/l, respectively; the corresponding values for the unsuppressed group were 242.2 and 564.7 nmol/l. Repeat ITT in the suppressed group 2–3 months after discontinuation of fluticasone revealed that all patients had a 60 minute serum cortisol greater than 500 nmol/l.
Conclusion: After therapy for asthma with inhaled fluticasone at approximately 500 μg daily for up to 16 weeks, half the children had evidence of adrenal suppression.
- ACTH, adrenocorticotropin
- HPA, hypothalamic-pituitary-adrenal
- ITT, insulin tolerance test
- insulin tolerance test
Statistics from Altmetric.com
Asthma is a chronic inflammatory disease of the medium and small airways which is increasingly prevalent among children worldwide. Oral corticosteroids, which have potent anti-inflammatory actions, remain the treatment of choice for severe chronic cases. However, the adverse effects of long term administration of oral corticosteroids, in particular suppression of hypothalamic-pituitary-adrenal (HPA) axis, preclude their routine and/or prolonged use. With the advent of inhaled corticosteroids, direct and immediate delivery of the small doses to the airways is possible, resulting in fewer undesirable systemic effects.1
Inhaled fluticasone propionate is a new topically active corticosteroid,2 twice as potent as beclomethasone and budesonide.3,4 Systemic absorption of fluticasone through the gastrointestinal tract and the lung is low. It has been claimed that inhalation of fluticasone produces negligible side effects, including HPA axis suppression.5 Based on morning serum cortisol levels, several authors have reported no inhibition of adrenal function associated with inhaled fluticasone use,6–8 even at high doses.9 By contrast, inhaled fluticasone therapy was found to decrease urinary excretion of cortisol in one study,10 and to reduce morning serum cortisol concentration by 17–43% in another study, even at conventional doses.11 Moreover, a recent survey in the United Kingdom found that acute adrenal crisis associated with inhaled fluticasone treatment was relatively frequent, despite it being the least prescribed inhaled corticosteroid.12
The contradictory reports as to the suppressive effect of adrenal function by inhaled fluticasone may reflect lack of sensitivity in some of the methods used. Urinary cortisol excretion and morning serum cortisol level provide information on basal endogenous adrenocortical activity only, and are not sensitive indices in predicting the ability of the HPA axis to respond to stress.
Adrenal function and its ability to respond to stress are best assessed by stimulation tests.13 The adrenocorticotropin (ACTH) test has been commonly employed to assess dynamic adrenal reserve.14,15 The standard ACTH test, using 250 μg ACTH, may give false negative results in the diagnosis of partial adrenal insufficiency.16 With the low dose ACTH test, partial adrenal suppression was found in 67% of the children treated with inhaled fluticasone in doses of 750 μg daily.17 This latter finding is important and requires confirmation by other methods of adrenal stimulation, such as the insulin tolerance test (ITT).
The ITT is considered by some investigators to be the gold standard in assessing the integrity of the entire HPA axis.16,18,19 Since the adrenal insufficiency induced by inhaled fluticasone use is usually partial rather than complete,15,16 a sensitive test is desirable. The ITT is recognised as potentially hazardous, with reports of fatalities due to failure to take precautions against hypoglycaemia, and inappropriate glucose administration.20 However, with full awareness of the potential risks, and the appropriate precautions and rescue measures for symptomatic hypoglycaemia, the ITT is relatively safe.21 We therefore carried out the present study to assess adrenal function using the ITT in asthmatic children treated with inhaled fluticasone after four months.
Children with moderately severe asthma in accordance with the criteria of the American Thoracic Society,22 were enrolled in the study. They had bronchial hyperresponsiveness to inhaled methacholine23 and had been followed regularly in the Pediatric Allergy Clinic at the Faculty of Medicine, Ramathibodi Hospital, Mahidol University. Written informed consent for enrolment in the study was obtained from their parents or legal guardians. The study was approved by the Ethics Committee of the Department of Pediatrics, Faculty of Medicine, Ramathibodi Hospital.
All the patients were treated with inhaled fluticasone and bronchodilators. The dose of inhaled fluticasone was given according to the degree of response to a provocative concentration of methacholine as reported by Sont and colleagues.24 Inhaled fluticasone was given via a standard Volumatic spacer twice daily. Patients were trained to inhale the medication properly and rinse their mouths immediately after each inhalation. Medication compliance was checked with diary card records.
Only patients receiving inhaled fluticasone for up to 16 weeks were included in the study. Patients treated with other medications for asthma, including ketotifen, sodium cromoglycate, systemic corticosteroids, and other topical corticosteroids, were excluded. Patients with contraindications to the ITT, namely pre-existing primary adrenal insufficiency, disorders of the central nervous system, and seizure disorders, were also excluded.
ITT was carried out in the paediatric clinical research unit by the paediatric endocrinologist (PM). After an overnight fast, the patients were infused with intravenous regular insulin 0.1 U/kg at 8 am. Blood samples were obtained for determinations of serum cortisol at 0 minutes (basal) and 60 minutes, and for plasma glucose at 0, 15, 20, 30, 45, and 60 minutes.
The following protocol for precautions and rescue measures for hypoglycaemia during the ITT was strictly adhered to. A physician and a nurse assistant were present throughout the testing. Clinical indications of hypoglycaemia, namely mental confusion, drowsiness, sweating, palpitations, and pupillary dilatation were closely observed. An intravenous cannula was inserted and its patency maintained throughout the testing. A bottle of 10% glucose solution was connected to the infusion line via a three-way connection ready for instant infusion. If serious adverse events (alteration of consciousness and convulsions) developed, the child was immediately given a bolus of glucose 0.5 g/kg followed by continuous infusion of 10% dextrose solution at 0.1 ml/kg per minute until plasma glucose was maintained above 5.5 mmol/l. At the end of the test, the children had to eat and remain in the research unit for one hour before cannula removal.
Serum cortisol level was determined by immunochemiluminescent assay using a commercial kit (Immulite, Diagnostic Products Corporation, Los Angeles, CA, USA). The mean intra-assay coefficient of variation was 6.1%. Plasma glucose was assayed by the glucose dehydrogenase method.
The test was considered valid if the nadir plasma glucose was less than 2.2 mmol/l. The criterion for adrenal suppression was a 60 minute serum cortisol value of less than 500 nmol/l during the ITT.15,16,25 The laboratory reference range for basal morning serum cortisol was 140–550 nmol/l.
Statistical comparisons of parameters between the adrenal suppressed and unsuppressed groups were performed with the Kruskal-Wallis test. Multiple regression analyses were used to study relations between 60 minute serum cortisol level and other variables. A p value <0.05 was taken as statistically significant.
Eighteen children (10 boys and 8 girls), aged 7–17 years, were enrolled in the study (see table 1). The duration of inhaled fluticasone treatment ranged from 5 to 16 weeks. Fourteen patients received 500 μg/day of fluticasone, three received 750 μg/day, and one 250 μg/day. The daily dose per body surface area ranged from 221 to 735 μg/m2 with a median dose of 477 μg/m2 per day, nine patients receiving greater than and nine less than 500 μg/m2 per day. None had stigmata of Cushing’s syndrome or symptoms of adrenal insufficiency.
During the ITT, most subjects had mild symptoms of hypoglycaemia (sweating and palpitations) but none developed serious adverse events (altered consciousness and convulsions). Nine children were in the suppressed group (60 minute cortisol ⩽500 nmol/l) and the remaining nine were in the unsuppressed group (60 minute cortisol >500 nmol/l). Age, daily and cumulative fluticasone doses, and duration of treatment were not statistically different between groups (see table 1). Basal serum cortisol concentrations were also significantly higher in the unsuppressed group (p < 0.05; see table 1 and fig 1), with serum morning cortisol levels within the normal range in all nine of the unsuppressed group in contrast to only four of the suppressed group. Using an increase of serum cortisol equal to or more than 200 nmol/l above the baseline value as a criterion of normal adrenal reserve, all patients in the unsuppressed group and five in the suppressed group had normal adrenal responses. Suppression of adrenal function was apparently related to the dose of inhaled fluticasone, being found in six of nine patients receiving greater than 500 μg/m2 per day and in only three of nine receiving less than this dose. Multiple regression analyses revealed that 60 minute serum cortisol values correlated negatively with dose of fluticasone (μg/m2 per day) (r = −0.44, p = 0.027), and positively with basal cortisol values (r = 0.95, p = 0.003).
Adrenal function was reassessed in the suppressed group; the children underwent a second ITT 2–3 months after discontinuation of inhaled fluticasone. The duration of inhaled fluticasone therapy in this group ranged from 4 to 12 months. All had 60 minute serum cortisol greater than 500 nmol/l during the ITT (median 594; range 532–641 nmol/l), indicating recovery from adrenal suppression.
In our study, assessment of adrenal function was based on serum cortisol at 60 minutes, taking this to be the peak serum cortisol value. The reason for obtaining only one serum cortisol value at 60 minutes after insulin infusion instead of three values each at 30, 60, and 90 minutes, respectively was due to a limited budget. We believe that this was acceptable, given the report of Erturk et al that serum cortisol values at 60 minutes were mostly higher than or as high as those at 30 and 90 minutes.25
Our study shows that therapy with inhaled fluticasone in a dose of approximately 500 μg/m2 per day was associated with adrenal suppression in half the patients studied up to 16 weeks after starting treatment. This figure is slightly less than the 67% reported by Fitzgerald and colleagues.17 This discrepancy could be due to differences in the methods (ITT versus low dose ACTH test) and median fluticasone dose administered (500 versus 750 μg/day). Adrenal suppression was found in only 10–16% of adult patients treated with inhaled fluticasone 220–880 μg daily.26 These findings suggest that children are more vulnerable to adrenal suppression from inhaled fluticasone than adults. However, it should be remembered that children receiving the same daily doses of fluticasone to adults will be subjected to higher doses per unit body surface area. Symptomatic adrenal insufficiency is relatively common in children receiving moderate to high doses of inhaled fluticasone (250–1000 μg/day).27–30 However, although half of the children in our study had biochemical evidence of adrenal suppression, none had symptoms of adrenal insufficiency or stigmata of Cushing’s syndrome.
It is known that a higher dose and a longer duration of corticosteroid treatment increase the incidence of adrenal suppression.31,32 The median doses received by the suppressed and unsuppressed groups in our study were not different; but more patients in the former group were on greater than 500 μg/m2 per day of fluticasone than the latter group.
At present, inhaled fluticasone is frequently prescribed for asthmatic children. To our knowledge, the present study is the first to examine adrenal status in fluticasone treated patients using the ITT. While the latter is potentially dangerous, we believe that with full awareness of the necessary precautions and rescue measures the risk is minimal, and that this method is justified in documenting the safety of inhaled fluticasone. In keeping with Galloway et al, who reported no serious adverse events with 550 ITTs over a 10 year period,21 we encountered no adverse event in the current study.
In conclusion, the present study indicates that therapy with inhaled fluticasone propionate (about 500 μg/day) results in suppression of adrenal function in half of the 18 treated asthmatic children. This implies that children on fluticasone doses above the recommended amount (400 μg/day) may be at increased risk for developing acute adrenal crisis during stress. Paediatricians should be vigilant for symptoms and signs of adrenal insufficiency in such children so that prompt assessment of adrenal function and, when necessary, adrenal replacement, can be instituted.
The authors would like to thank all the patients and their parents for cooperation in the study, and Professor Phienvit Tantibhedhyangkul for the suggestion and assistance in manuscript revision. This study was funded by a grant from the Endocrine Division, Department of Pediatrics at the Faculty of Medicine, Ramathibodi Hospital.